COLO 320 Xenograft Model Service for Colon Cancer

The COLO 320 xenograft model offers a robust preclinical platform for evaluating therapeutic strategies against colon cancer, leveraging a well-characterized cell line with distinct neuroendocrine and adenocarcinoma features. At Alfa Cytology, we specialize in delivering high-quality, reproducible COLO 320 xenograft models tailored to your drug discovery and development needs. Our experienced team ensures rigorous quality control, standardized protocols, and comprehensive endpoint analysis to accelerate your preclinical research pipeline.

Overview of COLO 320 Xenograft Model for Colon Cancer

The COLO 320 cell line was originally established in 1977 from a moderately undifferentiated adenocarcinoma of the sigmoid colon in a 55-year-old Caucasian female patient. It represents a unique model in colorectal cancer research, exhibiting both epithelial and neuroendocrine differentiation characteristics. The cell line is notable for its production of multiple hormones including serotonin, norepinephrine, epinephrine, adrenocorticotropic hormone (ACTH), and parathyroid hormone, reflecting its mixed adenoneuroendocrine phenotype. Genetically, COLO 320 lacks mutations in major colorectal cancer driver genes such as KRAS, BRAF, PIK3CA, and PTEN, but carries a TP53 mutation (R248W) and displays MYC amplification, making it particularly valuable for studying alternative oncogenic pathways and APC-independent carcinogenesis.

In xenograft applications, COLO 320 demonstrates reliable tumorigenicity in immunodeficient mice, forming tumors that recapitulate key histological features of the original patient tumor. The model has been extensively utilized in studies evaluating antiangiogenic therapies, mesenchymal stem cell interactions, and chemotherapy response mechanisms. Its rapid proliferation rate (doubling time approximately 20--24 hours) and consistent growth patterns make it an efficient and cost-effective choice for preclinical drug efficacy studies. Researchers frequently employ COLO 320 xenografts to investigate signaling pathways involved in metastasis, cellular responses to hypoxia, and tumor microenvironment interactions, contributing significantly to the development of targeted therapeutic strategies for colorectal carcinoma.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting colon adenocarcinoma with neuroendocrine features.
• Mechanistic Studies: Investigating the complex molecular pathways driving colon cancer progression through MYC amplification and TP53 mutation, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment, particularly for hormone production and neuroendocrine differentiation markers.

Figure 1. Colo 320 cell culture. Day 7 (a), day 14 (b) scale bars: 100 um. (Akay Sazaklioglu, S, et al., 2025)

Cell Line Information: COLO 320

The COLO 320 cell line family includes two major sublines: COLO 320DM (Double Minutes) and COLO 320HSR (Homogeneously Staining Regions), both derived from the same parental tumor. Its mixed adenoneuroendocrine phenotype and MYC amplification make it unique among available colon cancer cell lines and essential for preclinical research targeting alternative oncogenic pathways in colorectal carcinoma.

Our Services

Alfa Cytology is your trusted partner for COLO 320 xenograft model services, offering end-to-end preclinical solutions from model establishment to comprehensive endpoint analysis. Our state-of-the-art facilities, stringent quality assurance protocols, and dedicated scientific team ensure that every study is conducted with the highest standards of reproducibility and data integrity. Whether you require standard subcutaneous xenografts, orthotopic implantations, or customized study designs with specific endpoint measurements, we deliver tailored solutions to meet your unique research objectives. Partner with Alfa Cytology to accelerate your colon cancer drug development pipeline with confidence and precision.

Workflow of COLO 320 Xenograft Model Construction

The construction of COLO 320 xenograft models follows a standardized, multi-step workflow designed to ensure reproducibility, ethical compliance, and scientific rigor. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Line Preparation and Quality Control: COLO 320 cells are revived from authenticated cryopreserved stocks and cultured under standardized conditions (RPMI-1640 with 10% FBS, 37 degrees C, 5% CO2). Cells undergo mycoplasma testing, STR authentication, and viability assessment before inoculation to ensure genetic stability and contamination-free status.
2. Animal Model Selection and Preparation: Immunodeficient mice (typically athymic nude mice or NOD-SCID mice, 6--8 weeks old) are acclimatized under specific pathogen-free (SPF) conditions for at least one week. Health status is verified prior to tumor cell inoculation.
3. Tumor Cell Inoculation: COLO 320 cells are harvested at logarithmic growth phase, washed, and resuspended in serum-free medium mixed with Matrigel (1:1 ratio) to enhance tumor take rates. A standardized cell suspension (typically 1x10^6 to 5x10^6 cells in 100--200 uL) is injected subcutaneously into the flank or orthotopically into the cecal wall, depending on study design.
4. Tumor Monitoring and Growth Assessment: Tumor development is monitored twice weekly using digital caliper measurements. Tumor volume is calculated using the modified ellipsoid formula (V = 0.5 x length x width^2). Mice are weighed regularly, and general health status is assessed according to institutional animal care guidelines.
5. Endpoint Analysis and Sample Collection: Upon reaching predetermined endpoint criteria (typically tumor volume of 1,000--1,500 mm^3 or study duration of 4--6 weeks), mice are humanely euthanized. Tumors are excised, weighed, and processed for downstream analyses including histopathology (H&E staining), immunohistochemistry (IHC), biomarker expression, and molecular profiling.
6. Data Documentation and Reporting: All experimental data, including tumor growth curves, body weight monitoring, survival records, and histological findings, are compiled into a comprehensive study report with statistical analysis to support regulatory submission and publication requirements.

Figure 2: Schematic workflow illustrating the derivation and construction of the COLO 320 Xenograft Model at Alfa Cytology.

Case Study-COLO 320 Xenograft Model Development

Alfa Cytology has successfully established and validated COLO 320 xenograft models for multiple preclinical drug development programs targeting colon cancer. Our case studies demonstrate consistent tumor take rates exceeding 90%, with reproducible growth kinetics and histopathological features mirroring the original patient tumor characteristics. Studies have evaluated diverse therapeutic modalities including cytotoxic agents, targeted small molecules, and antiangiogenic therapies, with comprehensive endpoint analyses encompassing tumor growth inhibition, biomarker modulation, and survival benefit assessment. Detailed datasets, including tumor growth curves, pharmacokinetic profiles, and histological validation reports, are available upon request. Contact our scientific team to discuss how our validated COLO 320 xenograft platform can support your specific drug development program.

Why Choose Alfa Cytology?

Alfa Cytology stands out as a premier provider of COLO 320 xenograft model services, combining scientific expertise, operational excellence, and client-centric flexibility to deliver superior preclinical research outcomes. Our commitment to quality and innovation ensures that your drug development programs receive the robust data support they need.

• Verified Cell Line Integrity: Extensive experience in colon cancer xenograft model development with validated COLO 320 platforms and proven track records across diverse therapeutic modalities.
• High Take Rates and Consistency: Rigorous cell line authentication and quality control protocols, including STR profiling, mycoplasma testing, and genetic stability monitoring, ensuring model reliability and data reproducibility.
• Comprehensive Analytical Support: Customizable study designs accommodating subcutaneous, orthotopic, and metastatic model configurations with flexible endpoint analyses tailored to your specific research questions.
• Tailored Study Designs: Comprehensive endpoint capabilities spanning tumor growth monitoring, histopathology, immunohistochemistry, biomarker analysis, and molecular profiling, all conducted in GLP-compliant environments.
• Standardized Protocols: Dedicated project management with transparent communication, timely reporting, and collaborative scientific consultation to align preclinical outcomes with your clinical development strategy.
• Dedicated Project Management: Competitive turnaround times and cost-effective pricing structures without compromising on scientific rigor or ethical standards in animal research.

Contact Us

Ready to advance your colon cancer preclinical research with our validated COLO 320 xenograft model service? We invite you to contact us or reach out to our scientific team today to discuss your project requirements, obtain a customized study proposal, or request detailed case study data. At Alfa Cytology, your research success is our priority, and we look forward to partnering with you to accelerate your therapeutic innovations from bench to bedside. Please reach out to us today via our inquiry form or email to learn more about our COLO 320 Xenograft Model services.

For research use only. Not intended for any clinical use.